Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK private surgery drive attacked in high-profile NHS resignation:

This article was originally published in Clinica

Executive Summary

The head of an NHS trust has resigned publicly in protest at the way the private sector has been granted priority access to a high-volume, low-cost surgery market, to the detriment of the more complex, high-investment activities demanded of NHS hospitals. While there is a place for private providers, their increasing use is threatening the very operability of the NHS and "pushing it to the point of no return", said Debbie Abrahams, chair of Rochdale Primary Care Trust. She voiced her criticism of the increasingly destabilising privatisation of the NHS during a march (Manchester, June 24) to protest at the service and staffing cuts linked to the current financial crisis. The issue of service privatisation and "US-style supermarket attitudes to health" are at the top of the agenda of the British Medical Association's annual conference, which begins today in Belfast (see related story).

You may also be interested in...

UK MHRA Relaxes GMP Rules For Drugs Imported From Third Countries During COVID-19 Outbreak

The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.

Interview: Arvelle Aims To Be Major Player In CNS

The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.

The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance

Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts